It’s one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for glioblastoma, there is no ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of ...

Novocure recently announced final results from a phase III EF-14 clinical trial of its Optune device for treatment of newly diagnosed glioblastoma (GBM). According to Novocure’s press release, the ...

The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...

Long-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone. Adding Optune to temozolomide improved overall survival (OS) by ...

A head patch device that delivers alternating electrical fields to the brain has been shown to significantly improve survival in newly diagnosed glioblastoma patients. Developed by Jersey, US-based ...

Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ...

LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...

Novocure (NVCR +1.91%) has been on a tremendous run-- up 17 times over the last five years -- leaving many investors thinking that they missed the boat. But in investing, winners keep on winning.